Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Monsanto/Evogene extend R&D deal

Monsanto and Israeli plant genomics company Evogene (Rehovot) are to extend their five- year research collaboration, which began in 2008, by a year to include Evogene’s Gene2Product computational technologies. The R&D deal is focused on identifying key plant genes related to yield, environmental stress and fertiliser utilisation in maize, soybeans, cotton and canola using Evogene’s Athlete computational technology. The addition of the Gene2Product platform will enhance trait efficacy and the development of candidate genes identified under the collaboration. The deal sees Evogene provide Monsanto with candidate genes discovered by its computational technologies, that will be validated by Evogene in model plants. Monsanto has exclusive licence rights to genes delivered by Evogene for commercialisation in maize, soybeans, canola and cotton. As part of the original agreement, Monsanto agreed, via a put option exercisable by Evogene, to invest $12 million in the company.



What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts